Another promising inhibitor is CDKI-73: this is an orally CDK9 inhibitor, able to induce apoptosis of AML cells through targeting of the anti-apoptotic proteins BCL-2, MCL-1 and XIAP [308], particularly active against MLL-rearranged AMLs [129]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.